- Home
- CELH vs ROIV Comparison
CELH vs ROIV Comparison
Compare CELH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | ROIV |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | 721 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 28.7B |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CELH | ROIV |
|---|---|---|
| Price | $28.09 | $39.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $64.81 | $28.94 |
| AVG Volume (30 Days) | 7.0M | ★ 8.2M |
| Earning Date | 05-08-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $1,318,014,000.00 | $8,260,000.00 |
| Revenue This Year | $37.04 | N/A |
| Revenue Next Year | $9.89 | $744.61 |
| P/E Ratio | $60.30 | ★ N/A |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $23.56 | $14.50 |
| 52 Week High | $66.74 | $42.50 |
Technical Indicators
Market Signals| Indicator | CELH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 63.02 |
| Support Level | $27.23 | $33.15 |
| Resistance Level | $30.20 | $42.50 |
| Average True Range (ATR) | 1.08 | 1.46 |
| MACD | -0.33 | 0.20 |
| Stochastic Oscillator | 27.46 | 75.14 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It focuses on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.